According to the latest report by IMARC Group, titled “Kidney Cancer Therapeutics and Diagnostics Market Report by Component (Drugs, Diagnostics), Cancer Types (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, and Others), Application (Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others), and Region 2025-2033,” the global kidney cancer therapeutics and diagnostics market size reached USD 5.4 Billion in 2024. Kidney cancer, also known as renal cancer, is diagnosed through a combination of medical history assessment, physical examination, and tests like computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET). It can also be diagnosed through biopsy and blood and urine tests. Besides this, its therapeutics encompass a range of treatment options aimed at managing and combating the growth of cancerous cells. It includes various therapies and surgeries, such as radical or partial nephrectomy, which help remove the tumor and affected kidney tissue. Additionally, kidney cancer therapeutics and diagnostics are used for removing cancer cells, controlling the spread, destroying tumors, and assisting physicians in planning treatments.
Global Kidney Cancer Therapeutics and Diagnostics Market Trends:
The increasing prevalence of kidney cancer worldwide due to the aging population, lifestyle factors like smoking and obesity, and genetic predisposition represent one of the key factors driving the market. Additionally, the rising awareness among individuals about kidney cancer symptoms and the importance of early detection and treatment are catalyzing the demand for kidney cancer therapeutics and diagnostics. Apart from this, the increasing use of genomic and personalized medicine for effective treatment approaches is contributing to the market growth. Furthermore, governing agencies of several countries are introducing awareness campaigns and healthcare programs, which is offering a favorable market outlook. Moreover, advancements in targeted therapies, immunotherapies, and personalized medicine and the development of more advanced diagnostic technologies, like novel imaging methods, liquid biopsies, genomic testing, and artificial intelligence (AI)-driven diagnostic tools, are propelling the market growth. Besides this, a rise in the improvement of healthcare infrastructure and facilities are positively influencing the market. Looking forward, the market value is projected to reach USD 9.2 Billion by 2033, expanding at a CAGR of 5.9% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Components Covered |
|
Cancer Types Covered | Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, Others |
Applications Covered | Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800